News & Events

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack—blocking the energy supply T cells depend on. The study, published Oct. 23 in Nature, points toward a promising new immunotherapy approach for ovarian cancer, which is notoriously aggressive and hard to treat.

A significant obstacle in treating ovarian cancer is the...

Investigators from Weill Cornell Medicine have discovered a defense mechanism that protects skin cancer cells from oxidative stress and helps them spread. The findings suggest a new drug target that could lead to therapies for deadly metastatic skin cancer.

When cancer cells colonize vital organs, they enter hostile territory, making it difficult to metastasize. Melanoma cells, for instance, experience high levels of oxidative stress in the bloodstream and at distant sites that kill...

A new artificial intelligence-based system can accurately assess the chromosomal status of in vitro-fertilized (IVF) embryos using only time-lapse video images of the embryos and maternal age, according to a study from investigators at Weill Cornell Medicine.

The new system, called "BELA,” and described in a paper published Sept. 5 in Nature Communications, is the team’s latest AI-based platform for assessing whether an...

Health care in the United States is at a crossroads, said U.S. Food and Drug Administration Commissioner Dr. Robert M. Califf, in large part due to a confluence of post-COVID disinformation, rising cardiovascular mortality rates, a heavier burden of chronic diseases and decreased life expectancy.

New York state however stands out as a bright spot. The state’s success is one of the reasons that brought Dr. Califf...

It may soon be possible to determine which patients with a type of liver cancer called hepatocellular carcinoma would benefit from immunotherapy, according to a preclinical study by Weill Cornell Medicine investigators.

The study, published Oct. 17 in Molecular Cell, provides new insights into a pair of proteins, called p62 and NBR1, and their opposing functions in regulating the interferon response in...

The first randomized, placebo-controlled clinical trial evaluating the impact of therapeutic monoclonal antibodies on the risk of developing long COVID was led by researchers at Weill Cornell Medicine. The study, published Sept. 1 in eClinicalMedicine, details an international, multicenter phase 2/3 clinical trial that found a combination of amubarvimab and romlusevimab did not reduce the...

Immune cells called monocytes produce a key inflammatory protein called interleukin-1 beta (IL-1β) through an unconventional pathway in patients with systemic lupus erythematosus, commonly referred to as lupus, according to a new study by Weill Cornell Medicine investigators.

The findings, published Oct. 7 in Immunity, could lead to new treatments targeting IL-1β to better manage inflammation in patients who don...

Dr. Ali Jalali, an assistant professor of population health sciences at Weill Cornell Medicine, was awarded the prestigious National Institutes of Health (NIH) Director’s New Innovator Award through its Helping to End Addiction...

A new technology enables the control of specific brain circuits non-invasively with magnetic fields, according to a preclinical study from researchers at Weill Cornell Medicine, The Rockefeller University and the Icahn School of Medicine at Mount Sinai. The technology holds promise as a powerful tool for studying the brain and as the basis for future neurological and...

How bladder cancer originates and progresses has been illuminated as never before in a study led by researchers at Weill Cornell Medicine and the New York Genome Center. The researchers found that antiviral enzymes that mutate the DNA of normal and cancer cells are key promoters of early bladder cancer development, and that standard chemotherapy is also a potent source of mutations. The researchers also discovered that overactive genes within abnormal...

Dr. Randy Longman, director of the Jill Roberts Center for Inflammatory Bowel Disease and an associate professor of medicine at Weill Cornell Medicine, and colleagues have received the NIH Director’s...

The possibility of parental disclosure through online patient portals led older adolescents to hesitate in sharing complete health information with doctors, putting them at risk of missed diagnoses and treatments, a new study by Weill Cornell Medicine researchers found.

The...

Removing protected class regulation from Medicare prescription drug policies could greatly reduce the United States' prescription drug spending—this could have saved potentially $47 billion between 2011-2019, according to Weill Cornell Medicine researchers.

The study, published Oct. 7 in Health Affairs, aims to inform policymakers' debates about Medicare Part D covering the expense of all drugs in six "protected...

Dr. Alessandro Fichera, a prominent colorectal surgeon, has been named chief of the Division of Colorectal Surgery at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, effective Oct. 14.

In his new role, Dr. Fichera leads a world-class team of colorectal surgeons that uses state-of-the-art technologies and innovative surgical techniques to provide...

NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine have received the Emergency Medicine Wellness Center of Excellence Award from the American College of Emergency...

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to less invasiveness and weaker biological activity, according to a multicenter study conducted at Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and other institutions.

The...

Weill Cornell Medicine investigators have found that two genetic variants that confer high risk of Alzheimer’s disease (AD) together trigger a harmful inflammatory response in the brain’s immune cells, particularly in females, in a preclinical model.

The findings, published Sept. 30 in Neuron, emphasize the importance of considering sex differences in Alzheimer’s research – a step that could ultimately lead to...

Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune checkpoint inhibitor therapy, according to a preclinical study led by researchers at Weill Cornell Medicine. The findings suggest a potential strategy for enhancing the potency of anticancer immunotherapies.

In the...

A powerful new analytical tool offers a closer look at how tumor cells “shape-shift” to become more aggressive and untreatable, as shown in a study from researchers at Weill Cornell Medicine and the New York Genome Center.

A tumor cell shape-shifts by changing its cell type or state, thus altering its basic pattern of activity and perhaps even its appearance. This changeability or “plasticity” is a characteristic of cancer that leads to diverse...